Engineering luminescent biosensors for point-of-care SARS-CoV-2 antibody detection

Current serology tests for SARS-CoV-2 antibodies mainly take the form of enzyme-linked immunosorbent assays or lateral flow assays, with the former being laborious and the latter being expensive and often lacking sufficient sensitivity and scalability. Here we present the development and validation...

Descripción completa

Detalles Bibliográficos
Autores principales: Elledge, Susanna K., Zhou, Xin X., Byrnes, James R., Martinko, Alexander J., Lui, Irene, Pance, Katarina, Lim, Shion A., Glasgow, Jeff E., Glasgow, Anum A., Turcios, Keirstinne, Iyer, Nikita, Torres, Leonel, Peluso, Michael J., Henrich, Timothy J., Wang, Taia T., Tato, Cristina M., Leung, Kevin K., Greenhouse, Bryan, Wells, James A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7444307/
https://www.ncbi.nlm.nih.gov/pubmed/32839788
http://dx.doi.org/10.1101/2020.08.17.20176925
Descripción
Sumario:Current serology tests for SARS-CoV-2 antibodies mainly take the form of enzyme-linked immunosorbent assays or lateral flow assays, with the former being laborious and the latter being expensive and often lacking sufficient sensitivity and scalability. Here we present the development and validation of a rapid, low-cost solution-based assay to detect antibodies in serum, plasma, whole blood, and saliva, using rationally designed split luciferase antibody biosensors (spLUC). This new assay, which generates quantitative results in as short as 5 minutes, substantially reduces the complexity and improves the scalability of COVID-19 antibody tests for point-of-care and broad population testing.

Ejemplares similares